<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05124678</url>
  </required_header>
  <id_info>
    <org_study_id>IDI SRC Ref:16/2020</org_study_id>
    <nct_id>NCT05124678</nct_id>
  </id_info>
  <brief_title>Pharmacogenetics-guided Isoniazid Dosing in TB-HIV</brief_title>
  <acronym>PHINX</acronym>
  <official_title>A Phase II Trial to Describe the Pharmacokinetics, Safety and Efficacy of Pharmacogenetics-guided Dosing of Isoniazid in Patients With HIV-associated TB</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Makerere University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current TB treatment as recommended by World Health Organization (WHO) although capable&#xD;
      of achieving 85% cure rates, has limitations, in particular drug interactions, toxicities,&#xD;
      and the long treatment duration which increases the possibility of nonadherence.&#xD;
&#xD;
      Sub-therapeutic isoniazid concentrations were demonstrated in several studies, including our&#xD;
      previous work, carried out among patients with tuberculosis receiving the standard dose&#xD;
      (5mg/kg) of isoniazid. The investigators found 78% of patients with HIV had isoniazid&#xD;
      concentrations below the recommended threshold. Malabsorption, drug-drug interactions, poor&#xD;
      adherence due to high pill burden may contribute to this. Pharmacogenetic variation may&#xD;
      compound these factors; isoniazid displays inter-individual variation in serum concentrations&#xD;
      and clearance due to differences in individual acetylator status.&#xD;
&#xD;
      While patients who metabolize isoniazid slowly (slow acetylators) are at a higher risk of&#xD;
      high drug concentrations and toxicities, fast acetylators are more likely to have&#xD;
      sub-therapeutic isoniazid concentrations.&#xD;
&#xD;
      In other studies, insufficient exposure with isoniazid, one of the cornerstone drugs for TB&#xD;
      treatment, has been associated with delayed sputum clearance, development of drug resistance,&#xD;
      and treatment failure.&#xD;
&#xD;
      Isoniazid is metabolized by the enzyme N-acetyl transferase, which in turn is controlled by&#xD;
      the N-acetyl transferase-2 (NAT-2) gene. Polymorphisms in this gene are responsible for the&#xD;
      N-acetylation phenotypes, with the distribution of NAT-2 fast, intermediate, and slow&#xD;
      acetylators being highly variable especially among African populations.&#xD;
&#xD;
      Given that NAT2 acetylator status explains most of the variability in INH exposures,&#xD;
      knowledge of NAT2 status may be a simpler way to select the right dose for individual&#xD;
      patients. The investigators will therefore provide higher doses to fast acetylators and&#xD;
      compare the isoniazid pharmacokinetics in these patients to slow acetylators who receive the&#xD;
      standard dose, who are more likely to already be achieving target concentrations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      N-acetyl transferase genotyping will be performed on HIV infected patients diagnosed with T&#xD;
      B. Slow acetylators will be initiated on the standard dose of isoniazid (5mg/kg) while fast&#xD;
      and intermediate acetylators will be initiated on 10mg/kg of isoniazid. All other TB drugs&#xD;
      will be given at their standard doses.&#xD;
&#xD;
      Monitoring for toxicities will be performed every two weeks (including ALT and screening for&#xD;
      peripheral neuropathy) and isoniazid concentrations will be measured four weeks after&#xD;
      initiating treatment at Ohr, 30mins, 1 hr, Thr and 4hr following observed drug intake.&#xD;
&#xD;
      Patients will be continued on standard dose isoniazid after completing the first 8 weeks of&#xD;
      treatment (intensive phase).&#xD;
&#xD;
      Sputum cultures for mycobacteria will be performed at baseline, week 2, 4 and week 8. TB&#xD;
      treatment outcome will be assessed after 6 months of treatment.&#xD;
&#xD;
      Non-linear mixed effects modelling will be used to model PK-PD data taking into account&#xD;
      clinical and demographic factors like age, sex and BMI. The investigators will develop a&#xD;
      model to establish the population parameters for isoniazid (for example clearance, absorption&#xD;
      rate constant and volume of distribution) and the variability around these primary PK&#xD;
      parameters. The investigators will then use the model to derive secondary PK parameters,&#xD;
      namely area under the concentration-time curve (AUC) and maximum concentrations (Cmax) of&#xD;
      isoniazid for each participant. The investigators will compare the PK parameters of isoniazid&#xD;
      in fast/intermediate acetylators taking 10mg/kg and slow acetylators taking 5mg/kg of&#xD;
      isoniazid.&#xD;
&#xD;
      In addition to the main objectives of the study, the investigators will also compare the PK&#xD;
      in patients in the PG guided isoniazid dosing group to those in the historical cohort while&#xD;
      matching for NAT2 status, age and sex. In the historical cohort, NAT-2 acetlyator genotyping&#xD;
      was performed but patients received standard dosing regardless of NAT-2 acetylator status. In&#xD;
      this trial, the investigators will use pharmacogenetic guided therapy for all participants.&#xD;
      The investigators will therefore be able to compare the pharmacokinetic data above, safety&#xD;
      and efficacy in patients who received pharmacogenetic therapy and those who did not.&#xD;
&#xD;
      The investigators will use PK-PD models to describe the relationship between concentrations&#xD;
      and pharmacodynamic data (including toxicities and sputum conversion at week 8) in patients&#xD;
      on the different doses. In addition to this, the investigators will also make this same&#xD;
      comparison for patients in this study and those who did not receive PG guided therapy from&#xD;
      the historical cohort. The investigators will also compare the number of grade 3-5 adverse&#xD;
      events and time to sputum culture conversion in patients in patients who did and did not&#xD;
      receive PG guided therapy while matching for NAT2 status, age and sex&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 18, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate the maximum concentrations of isoniazid stratified by NAT2 group</measure>
    <time_frame>Week 4 of treatment</time_frame>
    <description>Maximum concentrations (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimate the area under the concentration-time curve of isoniazid stratified by NAT2 group</measure>
    <time_frame>Week 4 of treatment</time_frame>
    <description>Area under the concentration-time curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimate the of Clearance isoniazid stratified by NAT2 group</measure>
    <time_frame>Week 4 of treatment</time_frame>
    <description>Clearance (L/h)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimate the Volume of distribution of isoniazid stratified by NAT2 group</measure>
    <time_frame>Week 4 of treatment</time_frame>
    <description>Volume of distribution (L)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug-induced hepatotoxicity</measure>
    <time_frame>Up to week 8 of treatment</time_frame>
    <description>Grade 2 or higher elevation in ALT or total bilirubin (drug-induced hepatotoxicity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other drug-related adverse events</measure>
    <time_frame>Up to week 8 of treatment</time_frame>
    <description>Other grade 2 or higher adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral neuropathy</measure>
    <time_frame>Up to week 8 of treatment</time_frame>
    <description>Grade 2 or higher peripheral neuropathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum culture conversion at week 8</measure>
    <time_frame>Up to week 8 of treatment</time_frame>
    <description>Proportion of patients who remain sputum positive</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Fast/intermediate acetylators</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm have fast/intermediate acetylator status from NAT2 genotyping.&#xD;
In the Intensive phase (Month 1-2) of treatment, they will receive; Oral Isoniazid 10mg/kg/day + Rifampicin, Ethambutol and Pyrazinamide at standard dose.&#xD;
In the continuation phase (Month 3 - 6 ) of treatment, they will receive; Oral Isoniazid 5mg/kg/day +Rifampicin at standard dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Slow acetylators</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants in this arm have a slow acetylator status from NAT2 genotyping. They will receive the standard of care. In the Intensive phase (Month 1-2) of treatment, they will receive; Oral Isoniazid 5mg/kg/day + Rifampicin, Ethambutol and Pyrazinamide at standard dose.&#xD;
In the continuation phase (Month 3 - 6 ) of treatment, they will receive; Oral Isoniazid 5mg/kg/day +Rifampicin at standard dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid Tablets</intervention_name>
    <description>High dose of isoniazid</description>
    <arm_group_label>Fast/intermediate acetylators</arm_group_label>
    <other_name>INH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Evidence of a personally signed and dated informed consent document indicating that&#xD;
             the subject (or a legal representative) has been informed of all pertinent aspects of&#xD;
             the study.&#xD;
&#xD;
          -  Subjects who are willing and able to comply with scheduled visits, treatment plan,&#xD;
             laboratory tests, and other study procedures.&#xD;
&#xD;
          -  Age of ≥18 years&#xD;
&#xD;
          -  Bacteriologically confirmed pulmonary TB (determined by Xpert, culture, or microscopy)&#xD;
&#xD;
          -  Confirmed HIV-1 infection.&#xD;
&#xD;
          -  On TB treatment for ≤ 7 days at the time of enrolment (Within this time, the patient&#xD;
             is still expected to have mycobacteria present in sputum and will provide enough time&#xD;
             to conduct screening procedures)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  TB infection of any organ/systems requiring TB treatment longer than 6 months&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Decompensated liver disease and/or aminotransferases &gt;2.5 x ULN&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Sekaggya-Wiltshire, MBChB, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Infectious Diseases Institute-Kampala</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Sekaggya-Wiltshire, MBChB, PhD</last_name>
    <phone>256772479791</phone>
    <email>csekaggya@idi.co.ug</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Meya, MBChB, PhD</last_name>
    <phone>256772543730</phone>
    <email>dmeya@idi.co.ug</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Infectious Diseases Institute</name>
      <address>
        <city>Kampala</city>
        <zip>256</zip>
        <country>Uganda</country>
      </address>
    </facility>
    <contact>
      <last_name>Christine Sekaggya-Wiltshire, MBChB, PhD</last_name>
      <email>csekaggya@idi.co.ug</email>
    </contact>
    <investigator>
      <last_name>Christine Sekaggya-Wiltshire, MBChB, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <reference>
    <citation>Adams LV, Mahlalela N, Talbot EA, Pasipamire M, Ginindza S, Calnan M, Haumba S. High completion rates of isoniazid preventive therapy among persons living with HIV in Swaziland. Int J Tuberc Lung Dis. 2017 Oct 1;21(10):1127-1132. doi: 10.5588/ijtld.16.0946.</citation>
    <PMID>28911356</PMID>
  </reference>
  <reference>
    <citation>World Health Organization, Guildelines for treatment of Tuberculosis. 2013.</citation>
  </reference>
  <reference>
    <citation>Han T. Effectiveness of standard short-course chemotherapy for treating tuberculosis and the impact of drug resistance on its outcome. JBI Libr Syst Rev. 2006;4(3):1-27.</citation>
    <PMID>27819814</PMID>
  </reference>
  <reference>
    <citation>Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, Reingold AL, Kenyon TA, Moeti TL, Tappero JW. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis. 2009 Jun 15;48(12):1685-94. doi: 10.1086/599040.</citation>
    <PMID>19432554</PMID>
  </reference>
  <reference>
    <citation>McIlleron H, Rustomjee R, Vahedi M, Mthiyane T, Denti P, Connolly C, Rida W, Pym A, Smith PJ, Onyebujoh PC. Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines. Antimicrob Agents Chemother. 2012 Jun;56(6):3232-8. doi: 10.1128/AAC.05526-11. Epub 2012 Mar 12.</citation>
    <PMID>22411614</PMID>
  </reference>
  <reference>
    <citation>Park JS, Lee JY, Lee YJ, Kim SJ, Cho YJ, Yoon HI, Lee CT, Song J, Lee JH. Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome. Antimicrob Agents Chemother. 2015 Oct 12;60(1):92-8. doi: 10.1128/AAC.00693-15. Print 2016 Jan.</citation>
    <PMID>26459901</PMID>
  </reference>
  <reference>
    <citation>Peloquin CA, Nitta AT, Burman WJ, Brudney KF, Miranda-Massari JR, McGuinness ME, Berning SE, Gerena GT. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother. 1996 Sep;30(9):919-25.</citation>
    <PMID>8876848</PMID>
  </reference>
  <reference>
    <citation>Sekaggya-Wiltshire C, von Braun A, Lamorde M, Ledergerber B, Buzibye A, Henning L, Musaazi J, Gutteck U, Denti P, de Kock M, Jetter A, Byakika-Kibwika P, Eberhard N, Matovu J, Joloba M, Muller D, Manabe YC, Kamya MR, Corti N, Kambugu A, Castelnuovo B, Fehr JS. Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations. Clin Infect Dis. 2018 Aug 16;67(5):708-716. doi: 10.1093/cid/ciy179.</citation>
    <PMID>29514175</PMID>
  </reference>
  <reference>
    <citation>Ding J, Thuy Thuong Thuong N, Pham TV, Heemskerk D, Pouplin T, Tran CTH, Nguyen MTH, Nguyen PH, Phan LP, Nguyen CVV, Thwaites G, Tarning J. Pharmacokinetics and Pharmacodynamics of Intensive Antituberculosis Treatment of Tuberculous Meningitis. Clin Pharmacol Ther. 2020 Apr;107(4):1023-1033. doi: 10.1002/cpt.1783. Epub 2020 Feb 29.</citation>
    <PMID>31956998</PMID>
  </reference>
  <reference>
    <citation>Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis. 1980 Jun;121(6):939-49.</citation>
    <PMID>6774638</PMID>
  </reference>
  <reference>
    <citation>Sloan D: Pharmacokinetic Variability in TB Therapy: Associations with HIV and Effect on Outcome. In: Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts, U.S.A; 2014</citation>
  </reference>
  <reference>
    <citation>Mah A, Kharrat H, Ahmed R, Gao Z, Der E, Hansen E, Long R, Kunimoto D, Cooper R. Serum drug concentrations of INH and RMP predict 2-month sputum culture results in tuberculosis patients. Int J Tuberc Lung Dis. 2015 Feb;19(2):210-5. doi: 10.5588/ijtld.14.0405.</citation>
    <PMID>25574921</PMID>
  </reference>
  <reference>
    <citation>Cordes H, Thiel C, Aschmann HE, Baier V, Blank LM, Kuepfer L. A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy. Antimicrob Agents Chemother. 2016 Sep 23;60(10):6134-45. doi: 10.1128/AAC.00508-16. Print 2016 Oct.</citation>
    <PMID>27480867</PMID>
  </reference>
  <reference>
    <citation>Katiyar SK, Bihari S, Prakash S, Mamtani M, Kulkarni H. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2008 Feb;12(2):139-45.</citation>
    <PMID>18230245</PMID>
  </reference>
  <reference>
    <citation>Sekaggya-Wiltshire C, von Braun A, Scherrer AU, Manabe YC, Buzibye A, Muller D, Ledergerber B, Gutteck U, Corti N, Kambugu A, Byakika-Kibwika P, Lamorde M, Castelnuovo B, Fehr J, Kamya MR. Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients. J Antimicrob Chemother. 2017 Apr 1;72(4):1172-1177. doi: 10.1093/jac/dkw534.</citation>
    <PMID>28108678</PMID>
  </reference>
  <reference>
    <citation>Denti P, Jeremiah K, Chigutsa E, Faurholt-Jepsen D, PrayGod G, Range N, Castel S, Wiesner L, Hagen CM, Christiansen M, Changalucha J, McIlleron H, Friis H, Andersen AB. Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania. PLoS One. 2015 Oct 26;10(10):e0141002. doi: 10.1371/journal.pone.0141002. eCollection 2015.</citation>
    <PMID>26501782</PMID>
  </reference>
  <reference>
    <citation>Aklillu E, Carrillo JA, Makonnen E, Bertilsson L, Djordjevic N. N-Acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in Ethiopians. Eur J Clin Pharmacol. 2018 Jul;74(7):903-911. doi: 10.1007/s00228-018-2448-y. Epub 2018 Mar 27.</citation>
    <PMID>29589062</PMID>
  </reference>
  <reference>
    <citation>Zaid RB, Nargis M, Neelotpol S, Sayeed MA, Banu A, Shurovi S, Hassan KN, Salimullah M, Ali L, Azad Khan AK. Importance of acetylator phenotype in the identity of Asian populations. Hum Biol. 2007 Jun;79(3):363-8.</citation>
    <PMID>18078208</PMID>
  </reference>
  <reference>
    <citation>Meier C, Brauchli YB, Jick SS, Kraenzlin ME, Meier CR. Use of depot medroxyprogesterone acetate and fracture risk. J Clin Endocrinol Metab. 2010 Nov;95(11):4909-16. doi: 10.1210/jc.2010-0032. Epub 2010 Aug 4.</citation>
    <PMID>20685865</PMID>
  </reference>
  <reference>
    <citation>Burhan E, Ruesen C, Ruslami R, Ginanjar A, Mangunnegoro H, Ascobat P, Donders R, van Crevel R, Aarnoutse R. Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients. Antimicrob Agents Chemother. 2013 Aug;57(8):3614-9. doi: 10.1128/AAC.02468-12. Epub 2013 May 20.</citation>
    <PMID>23689725</PMID>
  </reference>
  <reference>
    <citation>Migliori GB, Raviglione MC, Schaberg T, Davies PD, Zellweger JP, Grzemska M, Mihaescu T, Clancy L, Casali L. Tuberculosis management in Europe. Task Force of the European Respiratory Society (ERS), the World Health Organisation (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) Europe Region. Eur Respir J. 1999 Oct;14(4):978-92.</citation>
    <PMID>10573254</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 1, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacogenetics</keyword>
  <keyword>High-dose Isoniazid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isoniazid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual patient data (IPD) will made available to other researchers for further analysis or met-analysis upon reasonable request to the investigators.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>6 months after publication of study results.</ipd_time_frame>
    <ipd_access_criteria>A direct request shall be made to the investigators .</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

